CAS: 878739-06-1; 3-(2-Cyanopropan-2-yl)-N-(4-Methyl-3-((3-Methyl-4-Oxo-3,4-Dihydroquinazolin-6-yl)Amino)Phenyl)Benzamide

上下游产品

N-(3-Amino-4-Methylphenyl)-3-(2-Cyanopropan-2-yl)Benzamide 872090-71-6

N-(3-Amino-4-Methylphenyl)-3-(2-Cyanopropan-2-yl)Benzamide,6-溴-3-甲基喹唑啉-4(3H)-酮,Sodium T-Butanolate,R-(+)-1,1'-联萘-2,2'-双二苯膦置于(1E,4E)-1,5-Diphenylpenta-1,4-Dien-3-One;Palladium Sodium Hydroxide,乙酸乙酯,Nacl(Sat),Sodium Sulfate-Iii体系中,用 甲苯 作为反应溶剂,化学反应 12.0H,以to Give 91 Mg (59%) Of A Light Yellow Solid的收率获得产物3-(1-氰基-1-甲基乙基)-N-[3-[(3,4-二氢-3-甲基-4-氧代-6-喹唑啉基)氨基]-4-甲基苯基]苯甲酰胺
参考文献:Quinazolinone Derivatives And Their Use As B-Raf Inhibitors
标题:Quinazolinone Derivatives And Their Use As B-Raf Inhibitors
摘要:本发明涉及化学式(I)的化合物或其药学上可接受的盐,其具有b Raf抑制活性,因此对其抗癌活性有用,并且在人体或动物体的治疗方法中使用.本发明还涉及制造上述化学化合物的方法,包含它们的制药组合物以及在制造用于在温血动物(如人)中产生抗癌效果的药物中使用它们的用途.

专利信息

专利号:US-2025289827-A1
优先权日:2022-12-02
标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof
发明人：YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN
权利人:C4 THERAPEUTICS INC
摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.